Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials Journal Article
| Authors: | Shepherd, F. A.; Fossella, F. V.; Lynch, T.; Armand, J. P.; Rigas, J. R.; Kris, M. G. |
| Article Title: | Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials |
| Abstract: | The potential benefits of docetaxel (Taxotere; Aventis, Antony, France) to patients with previously-treated non-small cell lung cancer have been evaluated in two prospective randomized phase III trials. In one study, patients with stage IIIB/IV non-small cell lung cancer who had failed previous cisplatin-based chemotherapy were randomized to receive either docetaxel (100 or 75 mg/m2, once every 3 weeks) or best supportive care. Median survival was significantly longer for patients treated with docetaxel 75 mg/m2 (7.5 months ν 4.6 months) as was 1-year survival (37% ν 11%). A second trial, also in platinum-pretreated patients, randomized patients to docetaxel 100 mg/m2, docetaxel 75 mg/m2, or vinorelbine/ifosfamide. Median survival was similar across the three study groups. Thirty-two percent of patients assigned to docetaxel 75 mg/m2 and 21% to docetaxel 100 mg/m2, were alive at 1 year, versus 19% on the vinorelbine/ifosfamide arm. Docetaxel offers clinically meaningful benefits in the second-line setting. The recommended dose is 75 mg/m2 once every 3 weeks. The adverse events observed were predictable, tolerable, and manageable. These phase III trials showed that docetaxel provided clinical benefits to patients with non-small cell lung cancer. Copyright © 2001 by W.B. Saunders Company. |
| Keywords: | cancer chemotherapy; cancer survival; survival analysis; clinical trial; review; cisplatin; diarrhea; side effect; paclitaxel; neurotoxicity; quality of life; infection; lung toxicity; blood toxicity; lung non small cell cancer; nausea; carcinoma, non-small-cell lung; lung neoplasms; palliative therapy; antineoplastic agents, phytogenic; ifosfamide; docetaxel; asthenia; febrile neutropenia; chemotherapy induced emesis; randomized controlled trials; cardiotoxicity; taxoids; phase 3 clinical trial; morphine; navelbine; radiation-sensitizing agents; analgesic agent; fluid retention; clinical trials, phase ii; humans; human; priority journal |
| Journal Title: | Seminars in Oncology |
| Volume: | 28 |
| Issue: | Suppl. 2 |
| ISSN: | 0093-7754 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2001-02-01 |
| Start Page: | 4 |
| End Page: | 9 |
| Language: | English |
| PUBMED: | 11284623 |
| PROVIDER: | scopus |
| DOI: | 10.1016/S0093-7754(01)90297-0 |
| DOI/URL: | |
| Notes: | Export Date: 21 May 2015 -- Source: Scopus |
